Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Allergy Clinical Trials

A listing of Allergy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (70) clinical trials

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Study is conducted in 2 parts: part A and part B. Part A - Patients with moderate-to-severe AD will be randomized to receive dupilumab (dose 1) by auto-injector (AI) device or prefilled syringe. Once part A is completely enrolled, part B will randomize patients with moderate-to-severe AD to receive dupilumab ...


Efficacy and Safety of Dupilumab in Patients 12 to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

To demonstrate the efficacy of dupilumab as a monotherapy in patients ≥12 years to <18 years of age with moderate-to-severe atopic dermatitis (AD)


Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

Mepolizumab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that acts on Interleukin-5 (IL-5), which is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils; thereby reducing the production and survival of eosinophils which may be therapeutic in subjects with atopic dermatitis (AD). This study will ...


Treatment of Atopic Dermatitis by a Full Body Blue Light Device

Multicentric, placebo‐controlled, double‐blinded, three‐armed, prospective, randomized controlled trial.150 patients diagnosed with atopic dermatitis will be randomized to arm 1 (irradiation for 30min at 415nm wavelength), arm 2 (irradiation for 30min at 450nm wavelength), and arm 3 (irradiation for 30min at low‐dose (placebo)). Irradiation will be scheduled 3 times a week ...

Phase N/A

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

This study has a randomized, double-blind, placebo-controlled design to assess the efficacy, pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic dermatitis when applied BID to all atopic dermatitis lesions.


Dose-ranging Study of Nemolizumab in Atopic Dermatitis

The aim of the study is to assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe AD subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.


Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

The primary objective is to assess the safety and tolerability of AR101 when used in a CODIT™ regimen for approximately 6 months in peanut-allergic children.


Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe AD. Secondary objectives: To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo. Maintenance objective: To evaluate maintenance of effect with continued ...


A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

This study is a dose escalation study to determine a safe and tolerable dose of ASN002 for people with moderate to severe atopic dermatitis. This study will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling and skin biopsies. Subjects will also be assessed for improvement in their ...


A Study in Subjects With Moderate Atopic Dermatitis

The main objectives of this study are to: - Evaluate the safety and tolerability of ALX-101 Gel 1.5% and 5% when applied topically in subjects with moderate atopic dermatitis compared with a matching ALX-101 Gel Vehicle - Evaluate the dose-response relationship of ALX-101 Gel 1.5% and 5% when applied topically ...